Hype or hypervirulence: A reflection on problematic C. difficile strains

Virulence

Volumn 4, Issue 7, 2013, Pages 592-596

  Smits, Wiep Klaas ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti sigma factor; Clostridium difficile; Epidemic; Lineage; Sporulation; Toxin

Indexed keywords

CLOSTRIDIUM TOXIN; FIDAXOMICIN; METRONIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; GENE SEQUENCE; MORBIDITY; MORTALITY; MULTILOCUS SEQUENCE TYPING; MUTATION; NONHUMAN; POLYMERASE CHAIN REACTION; REVIEW; RIBOTYPING; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SPOROGENESIS;

CLOSTRIDIUM DIFFICILE;

ANTI-SIGMA FACTOR; CLOSTRIDIUM DIFFICILE; EPIDEMIC; LINEAGE; SPORULATION; TOXIN;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; RIBOTYPING; VIRULENCE; VIRULENCE FACTORS;

EID: 84885107065     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.26297     Document Type: Review

References (86)

1. Hall IC, O'Toole E. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child 1935; 49:390-402; http://dx.doi.org/10.1001/archpedi. 1935.01970020105010
2. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978; 298:531-4; PMID:625309; http://dx.doi. org/10.1056/NEJM197803092981003
3. Bartlett JG. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 2008; 46(Suppl 1):S4-11; PMID:18177220; http://dx.doi.org/10.1086/521865
4. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7:526-36; PMID:19528959; http://dx.doi.org/10.1038/nrmicro2164
5. Knetsch CW, Lawley TD, Hensgens MP, Corver J, Wilcox MW, Kuijper EJ. Current application and future perspectives of molecular typing methods to study Clostridium difficile infections. Euro Surveill 2013; 18:20381; PMID:23369393
6. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT, Kuijper EJ; ECDIS Study Group. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377:63-73; PMID:21084111; http:// dx.doi.org/10.1016/S0140-6736(10)61266-4
7. McDonald LC, Killgore GE, Thompson A, Owens RC Jr., Kazakova SV, Sambol SP, Johnson S, Gerding DN. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-41; PMID:16322603; http://dx.doi.org/10.1056/ NEJMoa051590
8. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-9; PMID:16322602; http:// dx.doi.org/10.1056/NEJMoa051639
9. Pépin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005; 173:1037-42; PMID:16179431; http://dx.doi.org/10.1503/cmaj.050978
10. Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, Roberts T, Croyle K, Krystofiak S, Patel-Brown S, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005; 26:273-80; PMID:15796280; http://dx.doi.org/10.1086/502539
11. O'Connor JR, Johnson S, Gerding DN. Clostridium difficile infection caused by the epidemic BI/ NAP1/027 strain. Gastroenterology 2009; 136:1913-24; PMID:19457419; http://dx.doi.org/10.1053/j. gastro.2009.02.073
12. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper EJ, Wilcox MH. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23:529-49; PMID:20610822; http://dx.doi.org/10.1128/CMR.00082-09
13. Viswanathan VK, Mallozzi MJ, Vedantam G. Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes 2010; 1:234-42; PMID:21327030; http://dx.doi.org/10.4161/gmic.1.4.12706
14. Goorhuis A, Bakker D, Corver J, Debast SB, Harmanus C, Notermans DW, Bergwerff AA, Dekker FW, Kuijper EJ. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008; 47:1162-70; PMID:18808358; http://dx.doi.org/10.1086/592257
15. Hensgens MP, Keessen EC, Squire MM, Riley TV, Koene MG, de Boer E, Lipman LJ, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases Study Group for Clostridium difficile (ESGCD). Clostridium difficile infection in the community: a zoonotic disease? Clin Microbiol Infect 2012; 18:635-45; PMID:22536816; http://dx.doi. org/10.1111/j.1469-0691.2012.03853.x
16. Keessen EC, Gaastra W, Lipman LJ. Clostridium difficile infection in humans and animals, differences and similarities. Vet Microbiol 2011; 153:205-17; PMID:21530110; http://dx.doi.org/10.1016/j.vetmic. 2011.03.020
17. Bakker D, Corver J, Harmanus C, Goorhuis A, Keessen EC, Fawley WN, Wilcox MH, Kuijper EJ. Relatedness of human and animal Clostridium difficile PCR ribotype 078 isolates determined on the basis of multilocus variable-number tandem-repeat analysis and tetracycline resistance. J Clin Microbiol 2010; 48:3744-9; PMID:20686080; http://dx.doi. org/10.1128/JCM.01171-10
18. He M, Miyajima F, Roberts P, Ellison L, Pickard DJ, Martin MJ, Connor TR, Harris SR, Fairley D, Bamford KB, et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 2013; 45:109-13; PMID:23222960; http:// dx.doi.org/10.1038/ng.2478
19. Aktories K. Bacterial toxins that target Rho proteins. J Clin Invest 1997; 99:827-9; PMID:9062338; http:// dx.doi.org/10.1172/JCI119245
20. Carter GP, Rood JI, Lyras D. The role of toxin A and toxin B in the virulence of Clostridium difficile. Trends Microbiol 2012; 20:21-9; PMID:22154163; http:// dx.doi.org/10.1016/j.tim.2011.11.003
21. Carter GP, Awad MM, Kelly ML, Rood JI, Lyras D. TcdB or not TcdB: a tale of two Clostridium difficile toxins. Future Microbiol 2011; 6:121-3; PMID:21366410; http://dx.doi.org/10.2217/ fmb.10.169
22. Carter GP, Rood JI, Lyras D. The role of toxin A and toxin B in Clostridium difficile-associated disease: Past and present perspectives. Gut Microbes 2010; 1:58-64; PMID:20664812; http://dx.doi.org/10.4161/ gmic.1.1.10768
23. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010; 467:711-3; PMID:20844489; http://dx.doi. org/10.1038/nature09397
24. Squire MM, Carter GP, Mackin KE, Chakravorty A, Norén T, Elliott B, Lyras D, Riley TV. Novel molecular type of Clostridium difficile in neonatal pigs, Western Australia. Emerg Infect Dis 2013; 19:790-2; PMID:23697508; http://dx.doi.org/10.3201/ eid1905.121062
25. Dupuy B, Govind R, Antunes A, Matamouros S. Clostridium difficile toxin synthesis is negatively regulated by TcdC. J Med Microbiol 2008; 57:685-9; PMID:18480323; http://dx.doi.org/10.1099/ jmm.0.47775-0
26. Matamouros S, England P, Dupuy B. Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol 2007; 64:1274-88; PMID:17542920; http://dx.doi.org/10.1111/j.1365-2958.2007.05739.x
27. Carter GP, Douce GR, Govind R, Howarth PM, Mackin KE, Spencer J, Buckley AM, Antunes A, Kotsanas D, Jenkin GA, et al. The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/ NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog 2011; 7:e1002317; PMID:22022270; http:// dx.doi.org/10.1371/journal.ppat.1002317
28. Curry SR, Marsh JW, Muto CA, O'Leary MM, Pasculle AW, Harrison LH. tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol 2007; 45:215-21; PMID:17035492; http://dx.doi. org/10.1128/JCM.01599-06
29. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366:1079-84; PMID:16182895; http://dx.doi.org/10.1016/S0140-6736(05)67420-X
30. Merrigan M, Venugopal A, Mallozzi M, Roxas B, Viswanathan VK, Johnson S, Gerding DN, Vedantam G. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol 2010; 192:4904-11; PMID:20675495; http://dx.doi.org/10.1128/ JB.00445-10
31. Vohra P, Poxton IR. Comparison of toxin and spore production in clinically relevant strains of Clostridium difficile. Microbiology 2011; 157:1343-53; PMID:21330434; http://dx.doi.org/10.1099/ mic.0.046243-0
32. Cartman ST, Kelly ML, Heeg D, Heap JT, Minton NP. Precise manipulation of the Clostridium difficile chromosome reveals a lack of association between the tcdC genotype and toxin production. Appl Environ Microbiol 2012; 78:4683-90; PMID:22522680; http://dx.doi.org/10.1128/AEM.00249-12
33. Bakker D, Smits WK, Kuijper EJ, Corver J. TcdC does not significantly repress toxin expression in Clostridium difficile 630ΔErm. PLoS One 2012; 7:e43247; PMID:22912837; http://dx.doi.org/10.1371/journal. pone.0043247
34. Lanis JM, Hightower LD, Shen A, Ballard JD. TcdB from hypervirulent Clostridium difficile exhibits increased efficiency of autoprocessing. Mol Microbiol 2012; 84:66-76; PMID:22372854; http://dx.doi. org/10.1111/j.1365-2958.2012.08009.x
35. Lanis JM, Barua S, Ballard JD. Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Pathog 2010; 6:e1001061; PMID:20808849; http://dx.doi.org/10.1371/journal. ppat.1001061
36. Stubbs S, Rupnik M, Gibert M, Brazier J, Duerden B, Popoff M. Production of actin-specific ADPribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 2000; 186:307-12; PMID:10802189; http://dx.doi. org/10.1111/j.1574-6968.2000.tb09122.x
37. Sundriyal A, Roberts AK, Ling R, McGlashan J, Shone CC, Acharya KR. Expression, purification and cell cytotoxicity of actin-modifying binary toxin from Clostridium difficile. Protein Expr Purif 2010; 74:42-8; PMID:20433927; http://dx.doi.org/10.1016/j. pep.2010.04.014
38. Carter GP, Lyras D, Allen DL, Mackin KE, Howarth PM, O'Connor JR, Rood JI. Binary toxin production in Clostridium difficile is regulated by CdtR, a LytTR family response regulator. J Bacteriol 2007; 189:7290-301; PMID:17693517; http://dx.doi.org/10.1128/ JB.00731-07
39. Geric B, Carman RJ, Rupnik M, Genheimer CW, Sambol SP, Lyerly DM, Gerding DN, Johnson S. Binary toxin-producing, large clostridial toxinnegative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J Infect Dis 2006; 193:1143-50; PMID:16544255; http://dx.doi. org/10.1086/501368
40. Schwan C, Nölke T, Kruppke AS, Schubert DM, Lang AE, Aktories K. Cholesterol-and sphingolipidrich microdomains are essential for microtubule-based membrane protrusions induced by Clostridium difficile transferase (CDT). J Biol Chem 2011; 286:29356-65; PMID:21705797; http://dx.doi.org/10.1074/jbc. M111.261925
41. Schwan C, Stecher B, Tzivelekidis T, van Ham M, Rohde M, Hardt WD, Wehland J, Aktories K. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog 2009; 5:e1000626; PMID:19834554; http://dx.doi.org/10.1371/journal. ppat.1000626
42. Papatheodorou P, Carette JE, Bell GW, Schwan C, Guttenberg G, Brummelkamp TR, Aktories K. Lipolysis-stimulated lipoprotein receptor (LSR) is the host receptor for the binary toxin Clostridium difficile transferase (CDT). Proc Natl Acad Sci U S A 2011; 108:16422-7; PMID:21930894; http://dx.doi. org/10.1073/pnas.1109772108
43. Papatheodorou P, Hornuss D, Nölke T, Hemmasi S, Castonguay J, Picchianti M, Aktories K. Clostridium difficile binary toxin CDT induces clustering of the lipolysis-stimulated lipoprotein receptor into lipid rafts. MBio 2013; 4:e00244-13; PMID:23631918; http:// dx.doi.org/10.1128/mBio.00244-13
44. Barbut F, Decré D, Lalande V, Burghoffer B, Noussair L, Gigandon A, Espinasse F, Raskine L, Robert J, Mangeol A, et al. Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actinspecific ADP-ribosyltransferase)-producing strains. J Med Microbiol 2005; 54:181-5; PMID:15673514; http://dx.doi.org/10.1099/jmm.0.45804-0
45. Bacci S, Mølbak K, Kjeldsen MK, Olsen KE. Binary toxin and death after Clostridium difficile infection. Emerg Infect Dis 2011; 17:976-82; PMID:21749757; http://dx.doi.org/10.3201/eid1706.101483
46. Stewart DB, Berg A, Hegarty J. Predicting recurrence of C. difficile colitis using bacterial virulence factors: binary toxin is the key. J Gastrointest Surg 2013; 17:118-24, discussion 124-5; PMID:23086451; http:// dx.doi.org/10.1007/s11605-012-2056-6
47. Hensgens MP, Kuijper EJ. Clostridium difficile infection caused by binary toxin-positive strains. Emerg Infect Dis 2013; 19:1539-40; PMID:23977836; http:// dx.doi.org/10.3201/eid1909.110814
48. Cairns MD, Stabler RA, Shetty N, Wren BW. The continually evolving Clostridium difficile species. Future Microbiol 2012; 7:945-57; PMID:22913354; http:// dx.doi.org/10.2217/fmb.12.73
49. Knetsch CW, Terveer EM, Lauber C, Gorbalenya AE, Harmanus C, Kuijper EJ, Corver J, van Leeuwen HC. Comparative analysis of an expanded Clostridium difficile reference strain collection reveals genetic diversity and evolution through six lineages. Infect Genet Evol 2012; 12:1577-85; PMID:22705462; http://dx.doi. org/10.1016/j.meegid.2012.06.003
50. Mastroeni P, Morgan FJ, McKinley TJ, Shawcroft E, Clare S, Maskell DJ, Grant AJ. Enhanced virulence of Salmonella enterica serovar typhimurium after passage through mice. Infect Immun 2011; 79:636-43; PMID:21098099; http://dx.doi.org/10.1128/ IAI.00954-10
51. Akerlund T, Svenungsson B, Lagergren A, Burman LG. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol 2006; 44:353-8; PMID:16455883; http://dx.doi. org/10.1128/JCM.44.2.353-358.2006
52. Fekety R, Silva J, Browne RA, Rifkin GD, Ebright JR. Clindamycin-induced colitis. Am J Clin Nutr 1979; 32:244-50; PMID:760500
53. Paredes CJ, Alsaker KV, Papoutsakis ET. A comparative genomic view of clostridial sporulation and physiology. Nat Rev Microbiol 2005; 3:969-78; PMID:16261177; http://dx.doi.org/10.1038/nrmicro1288
54. Brown DP, Ganova-Raeva L, Green BD, Wilkinson SR, Young M, Youngman P. Characterization of spo0A homologues in diverse Bacillus and Clostridium species identifies a probable DNA-binding domain. Mol Microbiol 1994; 14:411-26; PMID:7885226; http:// dx.doi.org/10.1111/j.1365-2958.1994.tb02176.x
55. Deakin LJ, Clare S, Fagan RP, Dawson LF, Pickard DJ, West MR, Wren BW, Fairweather NF, Dougan G, Lawley TD. The Clostridium difficile spo0A gene is a persistence and transmission factor. Infect Immun 2012; 80:2704-11; PMID:22615253; http://dx.doi. org/10.1128/IAI.00147-12
56. Underwood S, Guan S, Vijayasubhash V, Baines SD, Graham L, Lewis RJ, Wilcox MH, Stephenson K. Characterization of the sporulation initiation pathway of Clostridium difficile and its role in toxin production. J Bacteriol 2009; 191:7296-305; PMID:19783633; http://dx.doi.org/10.1128/JB.00882-09
57. Rosenbusch KE, Bakker D, Kuijper EJ, Smits WK. C. difficile 630Δerm Spo0A regulates sporulation, but does not contribute to toxin production, by direct high-affinity binding to target DNA. PLoS One 2012; 7:e48608; PMID:23119071; http://dx.doi. org/10.1371/journal.pone.0048608
58. Akerlund T, Persson I, Unemo M, Norén T, Svenungsson B, Wullt M, Burman LG. Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1. J Clin Microbiol 2008; 46:1530-3; PMID:18287318; http:// dx.doi.org/10.1128/JCM.01964-07
59. Burns DA, Heeg D, Cartman ST, Minton NP. Reconsidering the sporulation characteristics of hypervirulent Clostridium difficile BI/NAP1/027. PLoS One 2011; 6:e24894; PMID:21949780; http://dx.doi. org/10.1371/journal.pone.0024894
60. Burns DA, Heap JT, Minton NP. The diverse sporulation characteristics of Clostridium difficile clinical isolates are not associated with type. Anaerobe 2010; 16:618-22; PMID:20950700; http://dx.doi. org/10.1016/j.anaerobe.2010.10.001
61. Heeg D, Burns DA, Cartman ST, Minton NP. Spores of Clostridium difficile clinical isolates display a diverse germination response to bile salts. PLoS One 2012; 7:e32381; PMID:22384234; http://dx.doi. org/10.1371/journal.pone.0032381
62. Lawley TD, Clare S, Walker AW, Goulding D, Stabler RA, Croucher N, Mastroeni P, Scott P, Raisen C, Mottram L, et al. Antibiotic treatment of clostridium difficile carrier mice triggers a supershedder state, sporemediated transmission, and severe disease in immunocompromised hosts. Infect Immun 2009; 77:3661-9; PMID:19564382; http://dx.doi.org/10.1128/ IAI.00558-09
63. Sebaihia M, Wren BW, Mullany P, Fairweather NF, Minton N, Stabler R, Thomson NR, Roberts AP, Cerdeño-Tárraga AM, Wang H, et al. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet 2006; 38:779-86; PMID:16804543; http://dx.doi. org/10.1038/ng1830
64. Stabler RA, Gerding DN, Songer JG, Drudy D, Brazier JS, Trinh HT, Witney AA, Hinds J, Wren BW. Comparative phylogenomics of Clostridium difficile reveals clade specificity and microevolution of hypervirulent strains. J Bacteriol 2006; 188:7297-305; PMID:17015669; http://dx.doi.org/10.1128/ JB.00664-06
65. Johnson AP, Wilcox MH. Fidaxomicin: a new option for the treatment of Clostridium difficile infection. J Antimicrob Chemother 2012; 67:2788-92; PMID:22865382; http://dx.doi.org/10.1093/jac/ dks302
66. Baines SD, O'Connor R, Freeman J, Fawley WN, Harmanus C, Mastrantonio P, Kuijper EJ, Wilcox MH. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62:1046-52; PMID:18693234; http://dx.doi. org/10.1093/jac/dkn313
67. Spigaglia P, Barbanti F, Mastrantonio P; European Study Group on Clostridium difficile (ESGCD). Multidrug resistance in European Clostridium difficile clinical isolates. J Antimicrob Chemother 2011; 66:2227-34; PMID:21771851; http://dx.doi. org/10.1093/jac/dkr292
68. Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DD, Sferra TJ, Hernandez AV, Donskey CJ. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 2013; 68:1951-61; PMID:23620467; http://dx.doi.org/10.1093/jac/dkt129
69. Owens RC Jr., Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46(Suppl 1):S19-31; PMID:18177218; http://dx.doi. org/10.1086/521859
70. Goorhuis A, Debast SB, Dutilh JC, van Kinschot CM, Harmanus C, Cannegieter SC, Hagen EC, Kuijper EJ. Type-specific risk factors and outcome in an outbreak with 2 different Clostridium difficile types simultaneously in 1 hospital. Clin Infect Dis 2011; 53:860-9; PMID:21914851; http://dx.doi.org/10.1093/cid/ cir549
71. Denève C, Bouttier S, Dupuy B, Barbut F, Collignon A, Janoir C. Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. Antimicrob Agents Chemother 2009; 53:5155-62; PMID:19805572; http://dx.doi.org/10.1128/AAC.00532-09
72. Aldape MJ, Packham AE, Nute DW, Bryant AE, Stevens DL. Effects of ciprofloxacin on the expression and production of exotoxins by Clostridium difficile. J Med Microbiol 2013; 62:741-7; PMID:23429695; http://dx.doi.org/10.1099/jmm.0.056218-0
73. Keessen EC, Hensgens MP, Spigaglia P, Barbanti F, Sanders IM, Kuijper EJ, Lipman LJ. Antimicrobial susceptibility profiles of human and piglet Clostridium difficile PCR-ribotype 078. Antimicrob Resist Infect Control 2013; 2:14; PMID:23566553; http://dx.doi. org/10.1186/2047-2994-2-14
74. Spigaglia P, Barbanti F, Mastrantonio P, Brazier JS, Barbut F, Delmée M, Kuijper E, Poxton IR; European Study Group on Clostridium difficile (ESGCD). Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol 2008; 57:784-9; PMID:18480338; http://dx.doi.org/10.1099/ jmm.0.47738-0
75. Zaiss NH, Witte W, Nübel U. Fluoroquinolone resistance and Clostridium difficile, Germany. Emerg Infect Dis 2010; 16:675-7; PMID:20350385; http://dx.doi. org/10.3201/eid1604.090859
76. Stabler R, Dawson L, Wren B. Clostridium difficile using DNA microarrays. Methods Mol Biol 2010; 646:149-62; PMID:20597008; http://dx.doi. org/10.1007/978-1-60327-365-7_10
77. Stabler RA, He M, Dawson L, Martin M, Valiente E, Corton C, Lawley TD, Sebaihia M, Quail MA, Rose G, et al. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol 2009; 10:R102; PMID:19781061; http://dx.doi. org/10.1186/gb-2009-10-9-r102
78. Stabler RA, Dawson LF, Valiente E, Cairns MD, Martin MJ, Donahue EH, Riley TV, Songer JG, Kuijper EJ, Dingle KE, et al. Macro and micro diversity of Clostridium difficile isolates from diverse sources and geographical locations. PLoS One 2012; 7:e31559; PMID:22396735; http://dx.doi.org/10.1371/journal. pone.0031559
79. Dingle KE, Didelot X, Ansari MA, Eyre DW, Vaughan A, Griffiths D, Ip CL, Batty EM, Golubchik T, Bowden R, et al. Recombinational switching of the Clostridium difficile S-layer and a novel glycosylation gene cluster revealed by large-scale whole-genome sequencing. J Infect Dis 2013; 207:675-86; PMID:23204167; http://dx.doi.org/10.1093/infdis/jis734
80. Valiente E, Dawson LF, Cairns MD, Stabler RA, Wren BW. Emergence of new PCR ribotypes from the hypervirulent Clostridium difficile 027 lineage. J Med Microbiol 2012; 61:49-56; PMID:21903827; http:// dx.doi.org/10.1099/jmm.0.036194-0
81. Nyč O, Pituch H, Matějková J, Obuch-Woszczatynski P, Kuijper EJ. Clostridium difficile PCR ribotype 176 in the Czech Republic and Poland. Lancet 2011; 377:1407; PMID:21515161; http://dx.doi. org/10.1016/S0140-6736(11)60575-8
82. Tagashira Y, Kato H, Senoh M, Nakamura A. Two cases of fulminant colitis due to binary toxin-positive Clostridium difficile that are not PCR ribotype 027 or type 078. J Med Microbiol 2013; 62:1486-9; PMID:23558137; http://dx.doi.org/10.1099/ jmm.0.057968-0
83. Vedantam G, Clark A, Chu M, McQuade R, Mallozzi M, Viswanathan VK. Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response. Gut Microbes 2012; 3:121-34; PMID:22555464; http:// dx.doi.org/10.4161/gmic.19399
84. Cartman ST, Heap JT, Kuehne SA, Cockayne A, Minton NP. The emergence of 'hypervirulence' in Clostridium difficile. Int J Med Microbiol 2010; 300:387-95; PMID:20547099; http://dx.doi. org/10.1016/j.ijmm.2010.04.008
85. Biazzo M, Cioncada R, Fiaschi L, Tedde V, Spigaglia P, Mastrantonio P, Pizza M, Barocchi MA, Scarselli M, Galeotti CL. Diversity of cwp loci in clinical isolates of Clostridium difficile. J Med Microbiol 2013; 62:1444-52; PMID:23722432; http://dx.doi.org/10.1099/ jmm.0.058719-0
86. Spigaglia P, Barketi-Klai A, Collignon A, Mastrantonio P, Barbanti F, Rupnik M, Janezic S, Kansau I. Surfacelayer (S-layer) of human and animal Clostridium difficile strains and their behaviour in adherence to epithelial cells and intestinal colonization. J Med Microbiol 2013; 62:1386-93; PMID:23518658; http://dx.doi. org/10.1099/jmm.0.056556-0